Skip to main navigation Skip to search Skip to main content

A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Project: Research

Project Details

StatusActive
Effective start/end date10/1/24 → 12/21/27

Funding

  • Tiziana Life Sciences: $70,370.56